Conviction in the face of affliction: a case series of Jehovah’s Witnesses with myeloid malignancies
- 76 Downloads
Myeloid malignancies are challenging diseases to treat, and management of Jehovah’s Witnesses (JW) affected by them imposes additional complexities. More than 1.2 million JW lives in the USA, and based on a specific interpretation of several biblical verses, many JW believe that the receipt of blood products is directly against the will of God and thus forbidden irrespective of the clinical indication. Guidance for the receipt of specific fractions of plasma (e.g., cryoprecipitate, albumin, clotting factor concentrates) is unclear and as a result is left up to the individual to decide based on his or her own interpretation [1, 2]. Absence of treatment for the myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) will universally herald disease-related cytopenias and the need for blood product transfusion which if refused often will lead to death. Furthermore, standard therapies for these cancers are myelosuppressive and blood product transfusion is typically an...
RMS, MLX, and AMZ wrote the final manuscript. All authors approved the final manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Why don’t Jehovah’s Witnesses accept blood transfusions? (2018) Watch Tower Bible and Tract Society of Pennsylvania. www.jw.org. Accessed 30 Jan 2018
- 2.Jehovah’s Witnesses. 2014 Religious Landscape Study (2014)Google Scholar
- 3.Kaito K, Kobayashi M, Sakamoto M, Shimada T, Masuoka H, Nishiwaki K, Saeki A, Sekita T, Otsubo H, Hosoya T (1998) Combination chemotherapy with G-CSF, M-CSF and EPO: successful treatment for acute myelogenous leukemia without blood transfusion at lower medical costs. Acta Haematol 100(1):57–60. https://doi.org/10.1159/000040865 CrossRefPubMedGoogle Scholar
- 8.Yamamoto Y, Kawashima A, Kashiwagi E, Ogata K (2014) A Jehovah’s Witness with acute myeloid leukemia successfully treated with an epigenetic drug, azacitidine: a clue for development of anti-AML therapy requiring minimum blood transfusions. Case Rep Hematol 2014:141260–141264. https://doi.org/10.1155/2014/141260 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Lin CP, Huang MJ, Liu HJ, Chang IY, Tsai CH (1996) Successful treatment of acute promyelocytic leukemia in a pregnant Jehovah’s Witness with all-trans retinoic acid, rhG-CSF, and erythropoietin. Am J Hematol 51(3):251–252. https://doi.org/10.1002/(SICI)1096-8652(199603)51:3<251::AID-AJH20>3.0.CO;2-I CrossRefPubMedGoogle Scholar
- 19.Cardenas-Araujo D, Gonzalez-Lopez EE, Gonzalez-Leal XJ, Jaime-Perez JC, Gomez-Almaguer D (2016) A clinical challenge: treatment of acute myeloid leukemia in a Jehovah’s Witness. Rev Bras Hematol Hemoter 38(4):358–360. https://doi.org/10.1016/j.bjhh.2016.05.003 CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Laszlo D, Agazzi A, Goldhirsch A, Cinieri S, Bertolini F, Rabascio C, Pruneri G, Calabrese L, Cocquio A, Martinelli G (2004) Tailored therapy of adult acute leukaemia in Jehovah’s Witnesses: unjustified reluctance to treat. Eur J Haematol 72(4):264–267. https://doi.org/10.1111/j.0902-4441.2003.00211.x CrossRefPubMedGoogle Scholar
- 21.Biscoe A, Kidson-Gerber G (2015) ‘Avoidable’ death of a pregnant Jehovah’s Witness with acute promyelocytic leukaemia: ethical considerations and the internal conflicts and challenges encountered by practitioners. Intern Med J 45(4):461–462. https://doi.org/10.1111/imj.12711 CrossRefPubMedGoogle Scholar
- 22.Jansen AJ, Caljouw MA, Hop WC, van Rhenen DJ, Schipperus MR (2004) Feasibility of a restrictive red-cell transfusion policy for patients treated with intensive chemotherapy for acute myeloid leukaemia. Transfus Med 14(1):33–38. https://doi.org/10.1111/j.0958-7578.2004.00477.x CrossRefPubMedGoogle Scholar
- 25.Fitzgerald MC, Chan JY, Ross AW, Liew SM, Butt WW, Baguley D, Salem HH, Russ MK, Deasy C, Martin KE, Mathew JK, Rosenfeld JV (2011) A synthetic haemoglobin-based oxygen carrier and the reversal of cardiac hypoxia secondary to severe anaemia following trauma. Med J Aust 194(9):471–473PubMedGoogle Scholar